Point-of-care engagement is essential for converting investments in payer negotiations and copay programs into prescriptions.
That era is ending. Policy reform, economic pressure, and patient empowerment have fractured that reality into three distinct ...
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...
Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, hopes to use the conference to explore how ...
Counterfeit pharma networks are becoming more sophisticated—leveraging advanced packaging, fragmented logistics, and global ...
Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses how the convergence of patient access ...
The adoption of biosimilars is increasing, with a predicted global market CAGR of 18%, though uptake varies by market and is influenced by factors like rebate schemes and patent litigation.
In today’s Pharma Pulse, Augmentin XR is the first drug approved under the FDA's new CNPV pilot program and much more.
In addition, many adults (67%) also think policymakers should keep access- and coverage-related factors in mind, namely ...
In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.
Jay McHarg, CEO of AeroSafe Global, discusses the significance of rethinking the “last mile” as the first moment of patient care—using real-time Active Delivery Management—for proactive and improved ...
The 20th installment of Trade & Channel Strategies carried on with a focus on boosting access to medication.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback